Early-stage funding for European life sciences companies

We are a venture capital firm specialised in seed investment for innovative early stage European companies.

Our current portfolio comprises biotech, medtech and diagnostics companies, all working to develop truly disruptive solutions for high unmet medical needs.

Dezima and Acerta, multi-billion Euro success stories

BioGeneration was co-founder and investor in two of the most successful biotech startups in Europe: Acerta Pharma and Dezima Pharma. Acerta Pharma develops a new drug for the treatment of hematologic malignancies (leukemia) and was sold to AstraZeneca for up to US$ 7 billion. Dezima Pharma is developing a treatment for of a cardiovascular disorder (dyslipidemia) and was sold to Amgen for a deal amount of up to US$ 1.5 billion.

Shaping new life-science ventures

Our varied and complementary experience has been gained from working within small and large pharma and biotech companies. Based on this experience and through our extensive industry network, we are able to bring a range of sector-relevant expertise to help accelerate product development and shape the companies to become attractive investment opportunities for the industry.

Latest news

Synaffix announces expansion of license agreement with Shanghai Miracogen Inc. to a second ADC candidate

Jan 8, 2020

ion of existing deal with leading Chinese ADC developer Total of six partnered ADCs based on Synaffix’s proprietary GlycoConnect™ and HydraSpace™ ADC technologies now under development AMSTERDAM, NETHERLANDS – January 7, 2020 – Synaffix B.V., a biotechnology company...

NorthSea Therapeutics Announces US $40 Million Series B Financing to Complete Phase IIb ICONA study in NASH and to Advance Two Additional SEFAs into the Clinic

Jan 8, 2020

Two new US investors; lead investor, venBio Partners and Sofinnova Investments, join syndicate of existing investors Richard Gaster, M.D., Ph.D., Principal at venBio Partners, and Maha Katabi, Ph.D., CFA, Partner at Sofinnova Investments join the Board Proceeds will...

Confo Therapeutics reports grant of two key patents for ConfoBodies

Dec 2, 2019

Ghent, Belgium, 2 December 2019 – Confo Therapeutics, a pioneering biopharma company, today announces that it has been granted two key ConfoBodyTM patents derived from the patent estate known as the “Steyaert patents”. The Steyaert patents – named after Prof. Jan...

NST doses first patient in Phase 2b clinical study of icosabutate in NASH (‘ICONA’)

Sep 25, 2019

NorthSea Therapeutics B.V., (‘NST’) a Dutch biotech company developing novel and innovative strategies for the treatment of NASH (Non-alcoholic Steatohepatitis) and other metabolic, inflammatory and fibrotic diseases, today announces dosing of the first patient with...

News overview

Next events

LSX World Congres 2020

Jan 20, 2020

Edward will attend the LSX World Congres 2020 in London. https://www.lsxleaders.com/lsx-world-congress

Innovation for Health Rotterdam – February 13

Jul 4, 2019

Max will attend the Innovation for Health conference in Rotterdam. https://www.innovationforhealth.nl/

Event overview

Latest investments

Portfolio